Despite improved cognitive outcomes after the introduction of combination antiretroviral therapy (cART), HIV-infected individuals continue to show cognitive impairment, particularly in verbal episodic memory and executive function.1 Episodic memory is impaired in up to 50% of HIV-infected individuals,2 and these cognitive deficits predict daily functioning.3–5 HIV-associated deficits in verbal memory are characterized by deficits in executive control of encoding and retrieval mechanisms,6–8 a pattern consistent with a frontal–subcortical involvement. Dependence on illicit drugs is also consistently associated with deficits in cognitive function, including verbal memory9–14 and executive function.15–18 Given that the use of illicit substances is common in HIV-infected populations, it is important to understand how HIV infection and illicit drug use might interact to impact cognitive function.
A number of recent in vitro and in vivo studies suggest that cocaine directly affects the neuropathogenesis of HIV.19–31 Cocaine amplifies HIV replication,21,22,25,28,30 including in human astrocytes,29 which can function as cellular reservoirs for HIV in the brain.32 Cocaine may also increase HIV-infected monocyte migration across the blood–brain barrier.23,24 Cocaine enhances the neurotoxic effects of the HIV viral protein Tat.19,20,26,27,31 Similarly, opiates increase neurotoxicity of HIV proteins Tat33–35 and gp120.35 Importantly, cocaine and opiates, in combination with HIV proteins, negatively impact hippocampal neurogenesis.36 Given that the hippocampus is critical for episodic memory, translation of these preclinical findings into clinical studies may lend important new insights into memory function in HIV-infected cocaine users.
Although many studies have investigated the impact of illicit drug use on HIV disease progression, the effects of cocaine and heroin use on cognition in HIV-infected women have not been elucidated.37 Such studies are critical in light of the myriad sex differences in illicit substance use disorders. Women have higher current and lifetime use of cocaine and are more likely than men to become cocaine dependent.38–40 Women who use cocaine are 3 times more likely to become infected with HIV than women who do not use cocaine.41 Cocaine use is also associated with accelerated disease progression in women with HIV, even when statistically controlling for antiretroviral therapy (ART) use42,43 and medication adherence.44 For example, in the Women's Interagency HIV Study (WIHS), HIV-infected women who used crack cocaine were 3 times more likely to die of AIDS-related causes than women who did not use crack cocaine, even when controlling for adherence to highly active antiretroviral therapy.44 Studies of illicit drug use in women generally have not found an effect of opiates on HIV disease progression.43,45
Our aim was to investigate the impact of HIV infection and illicit drug use on cognition in women. We compared 3 categories of drug use: recent use, former use, and nonuse. Primary outcomes were measures of verbal learning and memory, processing speed, and executive function based on neuropsychological tests with demonstrated sensitivity to HIV-related neurocognitive dysfunction.46–50 We hypothesized that HIV and illicit drug use, especially cocaine use, would have an interactive effect on verbal learning and memory and executive function.
All participants were enrolled in the WIHS, the largest prospective, longitudinal, multicenter study of HIV progression in women.51,52 Study methodology, standardized data collection, and training of interviewers have been previously reported.51,52 We analyzed cross-sectional data from 947 HIV-infected and 443 HIV-uninfected control participants (mean age = 42.8, 64% African-American). The data were collected as part of a study of menopause, cognition, and mood that was incorporated into the WIHS core visits in April 2007 to April 2008 (WIHS visit 25).53 Extensive information on demographic and behavioral variables was obtained, including self-report of recent and past use of alcohol, marijuana, crack cocaine, powder cocaine, and heroin.
Altogether, 1901 participants were assessed during that WIHS core visit, and 1552 of those women completed the Hopkins Verbal Learning Test—Revised (HVLT-R). We excluded 157 of those participants because they reported: (a) primary language other than English (n = 14), (b) history of stroke/cerebrovascular accidents (n = 18), and/or (c) use of antipsychotic medication in the past 6 months (n = 130). A comparison of women who were included in this analysis (n = 1395, 73% of the overall sample) vs. those who were excluded (n = 506) showed similar rates of cocaine and heroin use, but women who were included completed more years of education (12.4 vs. 10.6 years, P < 0.001), performed better on the Wide Range Achievement Test—Revised (WRAT-R) (92.2 vs. 87.3, P < 0.001), were more likely to be African-American (64% vs. 41%, P < 0.001) and less likely to be Hispanic (19% vs. 48%, P < 0.001), were less likely to have depressive symptoms on the Center for Epidemiological Studies Depression scale (32% vs. 46%, P < 0.001) or report using antidepressant medication (12% vs. 19%, P < 0.001), and were more likely to smoke (72% vs. 66%, recent or former, P = 0.01) and use marijuana (75% vs. 60%, recent or former, P < 0.001).
Illicit Drug Use
The WIHS collects information on drug use at 6-month intervals consistent with the twice yearly WIHS visit schedule. Women are asked if they have used drugs since their last WIHS visit. If they have used drugs since their last WIHS visit, they are queried about the route of administration (smoking, sniffing, and injecting) of each substance and their frequency of use. For the current study, recent illicit drug use was defined as self-reported use of crack cocaine, powder cocaine, or heroin since the last WIHS study visit (past 6 months). Former use was defined as any lifetime use of cocaine and/or heroin but no use since the last WIHS study visit (past 6 months). Nonuse was defined as no lifetime use of cocaine and/or heroin. In follow-up analyses focusing on particular drugs, crack cocaine and powder cocaine were combined into one cocaine use variable, as there was insufficient statistical power to separate the 2 forms of the drug. Frequency data were categorized as once a month or less, at least once a week but less than once per day, or once a day or more.
Clinical Neuropsychological Measures
Participants completed the HVLT-R and Comalli Stroop test. The HVLT-R is a 12-item-list learning test used to measure verbal episodic memory.54 Outcomes include total words recalled on trial 1 (single trial learning) and across each of 3 learning trials (total learning), number of words recalled after a 25-minute delay (delayed recall), number of words correctly identified on a yes/no recognition test (recognition), percent retention (delayed recall/maximum score on trial 2 or 3), and learning slope. Recognition scores were calculated by subtracting the number of false positives (incorrectly responding "yes" to a word not presented) from the number of hits (correctly responding "yes" to a word that was presented). The Comalli Stroop test includes 3 trials55: trials 1 and 2 measure attention and processing speed and trial 3 measures response inhibition/executive function. On trial 1, participants name the colors of a series of squares. On trial 2, they read a series of color names printed in black ink. On trial 3, participants name the color of the ink but ignore the word (eg, when shown the word "red" printed in blue ink, say "blue" rather than red).55 Completion times for all 3 trials were recorded. The WRAT-R measured reading achievement56 and served as an index of educational quality.57
Sociodemographic covariates and risk factors for cognitive impairment were selected based on previous literature and included study site, age, years of education, race/ethnicity, WRAT-R, Center for Epidemiological Studies Depression scale (cutoff score of 16),58 recent self-reported use of antidepressant medication, and hepatitis C virus (HCV) seropositivity.48,59–66 Other covariates focused on risk behaviors and included smoking status (recent, former, and never), recent hazardous alcohol use (>7 drinks per week or more than 4 drinks in one sitting),67 and marijuana/hash use (recent, former, and never). Additional clinical variables of interest were cART use (ie, no cART, cART and <95% compliant, and cART and ≥95% compliant), recent CD4 count less than 200 cells per cubic millimeter, recent HIV viral load greater than 10,000, CD4 nadir less than 200 cells per cubic millimeter, and duration of ART use.
Five percent of participants were missing WRAT-R scores. Missing values were imputed using a regression-based technique with race/ethnicity, age, education, site, and employment as predictors. Time-related outcomes on the Stroop were log transformed to correct for skewness. All outcome measures were transformed to z scores to allow for comparison of beta weights across outcome measures in models controlling for the same covariates.
Differences in demographic, behavioral, and clinical characteristics as a function of serostatus, illicit drug use, and their interaction were examined using analyses of variance for continuous variables and χ2 tests for categorical variables. In the overall sample, we conducted 2 series of multivariable regression analyses. The first series focused on the independent effects of serostatus and illicit drug use, adjusting for age, years of education, WRAT-R, race/ethnicity, site, depressive symptoms, self-reported use of antidepressant medication and dementia/encephalopathy (n = 59), marijuana use, smoking, hazardous alcohol use, and HCV. We also adjusted for number of prior exposures to the Stroop (range 1–3). (The HVLT had not been previously administered.) The primary set of analyses focused on the interactive effect of serostatus and illicit drug use. When the interaction was significant, we further examined the effect of drug use and frequency within each serostatus group, controlling for the same set of covariates included in the first analyses. Other follow-up analyses focused on HIV-infected women and included recent CD4 count and HIV viral load, CD4 nadir, and use of ART. All P values are 2 sided. The statistical significance level was set at P < 0.05. Analyses were performed using SAS PROC GENMOD (version 9.2, SAS Institute Inc, Cary, NC).
Participants included 952 HIV-infected and 443 HIV-uninfected women. They ranged in age from 22 to 78 years (M = 42.8, SD = 9.5), with high minority representation (64% African-American, 19% Hispanic). Ten percent (n = 140) reported use of cocaine and/or heroin since the previous study visit 6 months earlier, 47% (n = 651) reported former use of cocaine and/or heroin, and 43% (n = 604) reported never using cocaine and/or heroin in their lifetime. Among recent drug users, 70% had recently used only cocaine, 24% had recently used both cocaine and heroin, and 6% had recently used only heroin. Recent cocaine users mainly smoked crack (74%) or snorted cocaine (26%). Primary modes of recent heroin intake were snorting (17%) and injecting (14%). Critically, as shown in the Supplemental Digital Content (see Table S1, http://links.lww.com/QAI/A394), the typical pattern of recent use was at least daily (32%) or weekly (38%) smoking of crack cocaine (eg, 73%).
Compared with HIV-uninfected women, HIV-infected women were older, had a higher minority representation, were more likely to be HCV seropositive and to use antidepressant medication and cigarettes, and were less likely to engage in hazardous drinking, marijuana, and powder cocaine use (P < 0.05, Table 1). Compared with nonusers, recent and former illicit drug users were older, less educated, were more likely to be HCV seropositive, reported more depressive symptoms and antidepressant medication use, and were more likely to smoke, use marijuana, crack cocaine, powder cocaine, heroin, and engage in hazardous drinking (P < 0.05). Among recent users, HIV-infected women were less likely to sniff/snort cocaine and less frequently injected heroin than HIV-uninfected women (P < 0.05, see Table S1, Supplemental Digital Content, http://links.lww.com/QAI/A394). Among HIV-infected women, recent users were less likely to be on cART and to adhere to their medication, were on ART for a shorter duration of time, and were diagnosed with HIV more recently than former and nonusers (P < 0.05).
Hopkins Verbal Learning Test—Revised
Table 2 shows the raw neuropsychological test scores as a function of serostatus and illicit drug use. HIV-infected women performed worse than HIV-uninfected women on total learning, learning slope, delayed recall, and recognition (P < 0.05, see Table 3). In adjusted analyses, recent illicit drug users performed worse than nonusers on learning slope (P = 0.04), delayed recall (P = 0.007), and recognition (P = 0.02). Recent drug users also performed worse than former drug users on recognition (P = 0.03). Former drug users did not perform differently than nonusers on any HVLT measure. The primary finding was that illicit drug use (recent vs. nonuse) interacted with serostatus to affect trial 1, total learning, learning slope, and delayed recall (P < 0.05, see Fig. 1), but not recognition (P = 0.73). Among HIV-infected women, recent illicit drug users performed worse than nonusers on total learning (B = −0.36, SE = 0.12, P = 0.002), learning slope (B = −0.42, SE = 0.12, P < 0.001), and delayed recall (B = −0.45, SE = 0.12, P < 0.001). In contrast, among the HIV-uninfected women, recent users performed similarly to nonusers on total learning (B = 0.22, SE = 0.15, P = 0.14), learning slope (B = 0.18, SE = 0.15, P = 0.23), and delayed recall (B = −0.05, SE = 0.15, P = 0.73). Whereas the interaction between serostatus and drug use for each of the 4 measures was driven by differences between recent users and nonusers at the level of serostatus, for trial 1 only the interaction was driven by differences between HIV-infected and uninfected women at the level of drug use. Specifically for trial 1, the interaction was driven by serostatus effects at the level of drug use; among recent users, HIV-infected women performed worse than HIV-uninfected women (B = −0.47, SE = 0.16, P = 0.004), whereas among nonusers, HIV+ women performed similar to HIV-uninfected women (B = −0.02, SE = 0.08, P = 0.84).
Follow-up analyses probed the interaction between serostatus and recent drug use further to assess which particular drug (ie, cocaine with or without heroin, heroin with or without cocaine) contributed to the interaction. Serostatus interacted with cocaine use (recent vs. nonuse, P < 0.05) and heroin use (recent vs. nonuse, P < 0.01) to impact total learning and learning slope. Serostatus interacted with cocaine use (nonuse vs. recent) but not heroin use to impact delayed recall (P = 0.04). Additional analyses focused on dose response by examining the frequency of smoking crack on total learning, learning slope, and delayed recall (see Table S2, Supplemental Digital Content, http://links.lww.com/QAI/A394). Serostatus interacted with frequency of crack use (≥1 week vs. nonuse) to affect total learning (P = 0.03) and delayed recall (P = 0.005). Again the patterns were that drug use impacted performance among HIV-infected women only.
In analyses of HIV-infected women only, the effects of illicit drug use (recent vs. nonuse) on total learning, learning slope, and delayed recall remained significant after controlling for disease characteristics (ie, CD4 count, viral load, medication use, duration on ART) (see Table 4). Recent users also performed worse than former users on learning slope and delayed recall, and former users performed worse than nonusers on delayed recall. Comparing recent users with nonusers on total learning and learning slope, recent heroin use predicted poorer performance (B = −0.42, SE = 0.19, P = 0.03 and B = −0.58, SE = 0.24, P = 0.01, respectively). Cocaine use predicted poorer performance on delayed recall (B = −0.32, SE = 0.15, P = 0.03). There was also a trend for heroin use to predict poorer performance on delayed recall (B = −0.34, SE = 0.20, P = 0.08). In HIV-infected women, the effects of smoking crack/cocaine at least once a week vs. nonuse remained significant on both total learning (B = −0.39, SE = 0.19, P = 0.04) and delayed recall (B = −0.40, SE = 0.19, P = 0.04) after controlling for disease characteristics (ie, CD4 count, viral load, medication use, duration on ART).
Neither HIV infection nor drug use significantly impacted performance on the Stroop test (trials 1 and 2 or trial 3, P > 0.05). In addition, there were no significant interactions between illicit drug use and serostatus on the Stroop test (P > 0.05).
The aim of this study was to investigate the separate and interactive effects of illicit drug use and HIV infection on verbal learning and memory, processing speed, and executive function. To our knowledge, this is the first study to examine this issue, and we provide new evidence that in women, recent illicit drug use may interact with HIV serostatus to negatively impact verbal learning and memory but not processing speed or response inhibition. The typical pattern of recent drug use was at least daily or weekly smoking of crack cocaine. The pattern of effects across different measures suggests that recent drug use (compared with nonuse) affects learning and memory more among HIV-infected than HIV-uninfected women. Cocaine use interacted with HIV serostatus to affect learning and delayed recall, but not recognition. Heroin interacted with HIV serostatus to affect only learning. Serostatus also interacted with frequency of crack cocaine use to negatively affect learning and delayed recall (but not recognition) more in HIV-infected women. HIV infection, regardless of substance use history, was associated with deficits in learning (ie, impaired total learning, learning slope) and delayed memory (impaired delayed recall, recognition), with no impairment in retention or attention (trial 1). Deficits in verbal learning and memory encoding might have important implications for clinical management of HIV, as neurocognitive deficits have been shown to relate to poor medication treatment adherence among HIV-infected individuals.68 Our results underscore the importance of effective substance abuse treatment in HIV-infected individuals.
Few studies have sufficient statistical power to test for an interactive effect of HIV and drugs of abuse on cognition.69 The HIV Neurobehavioral Research Center has investigated additive and potential interactive effects of methamphetamine and HIV. They found additive effects of methamphetamine use and HIV infection on neuropsychological function,70 neural and glial injuries,71 and cerebral blood flow.72 The only previous study to investigate the interactive effects of HIV and cocaine use on verbal memory (n = 237 gay and bisexual seropositive and seronegative African-American men) found no significant main effects for serostatus or cocaine use and no interaction of HIV and cocaine use on verbal memory, differences that were attributed to confounding effects of alcohol.73
Several studies have provided important insights into how HIV serostatus influences cognition among individuals using illicit substances.48,74–77 Compared with HIV-uninfected drug users, HIV-infected drug users performed worse on tests of procedural learning,74 prospective memory,75 decision making,78 and working memory,76,77 deficits consistent with the affinity of HIV for the striatum and prefrontal cortex. However, study samples were typically men, of small size (n < 100), and did not include a nondrug using comparison group.48,74–77 A study of 43 women with a history of illicit drug use did not identify a relationship with cocaine or heroin use within the past 12 months and noted no interaction between HIV status and recent drug use on verbal memory or any cognitive domain; however, cell sizes were small (eg, n = 9).79 We similarly did not find a difference between recent and former users on total learning or delayed recall.
In our full sample of HIV-infected and HIV-uninfected women, there were no differences between former drug users and nonusers on any neurocognitive outcome, suggesting recovery of cognitive function. In contrast, in our HIV-infected sample, former users performed worse than nonusers on delayed recall. This pattern provides further evidence that drug use has a stronger negative impact on cognitive function in HIV-infected women. Recent use may have a larger negative impact than past use because of the synergistic neurotoxicity of HIV viral proteins with cocaine and heroin, with potential for recovery of cognitive function with sustained abstinence.80–82
Other studies have looked within HIV-infected cohorts for effects of drug use on cognition, but without an HIV-uninfected control group. Our findings are consistent with other findings showing an effect of active cocaine dependence on delayed recall and visuospatial construction in HIV-infected individuals (n = 64, 72% men), with recall having the largest effect size (d = 0.93).83 As in the present study, CHARTER (75% men) found no impact of lifetime history of substance use on tests of processing speed and executive function.84 CHARTER also found that lifetime heroin dosage related to delayed memory. In comparison, we found that delayed memory related to recent use of cocaine, particularly use of crack cocaine more than once per week. Recent heroin use was associated with worse total learning in HIV-infected women. Recent stimulant use was associated with impairments in sustained attention in a sample of 40 HIV-infected individuals, but verbal memory was not examined and cocaine and methamphetamine use were combined.85
Contrary to our hypothesis, serostatus and illicit drug use did not interact to affect inhibitory control. The scientific literature is mixed with respect to whether drug use impacts Stroop performance. A study of 159 men with at least one substance use disorder found a negative effect of HIV infection on performance during the incongruent condition of a computerized Reaction Time Stroop.48 Other studies have failed to find a negative effect of cocaine use on Stroop performance in HIV-uninfected individuals10,15,86 but have found effects on other executive measures such as the go/no test.15,16,87
The use of the HVLT precludes a clear understanding of whether the interactive effects of HIV and recent drug use represent a deficit in acquisition/encoding, retention, and/or retrieval. However, the pattern of interactions provides tentative support of potential effects on acquisition and retrieval, with spared retention. Specifically, HIV serostatus interacted with recent drug use to affect acquisition (total learning and learning slope) and retrieval (impaired delayed recall but spared recognition), with no effect on retention. Interestingly, this same pattern of effects was evident in follow-up analyses examining the impact of cocaine use specifically and frequency of crack cocaine use. Crack cocaine was the primary drug of choice among recent users. Moreover, analyses of recent drug use in HIV-infected women alone showed deficits in acquisition (total learning and learning slope) and retrieval (impaired delayed recall but spared recognition), with no effect on retention. This pattern of interactive effects differs from the pattern of main effects associated with HIV serostatus and recent drug use, which were characterized by deficits in acquisition only. The apparent pattern of interactive effects on acquisition and retrieval suggests that HIV and cocaine might interact to influence subcortical–prefrontal circuitry. Chronic cocaine use has been associated with anatomical changes, cerebrovascular defects, and functional alterations in the prefrontal cortex.88–92 Given the known executive component, such as encoding strategies, on episodic memory performance, deficits in subcortical–prefrontal circuitry may contribute to deficits in verbal memory.93–95 A neuroimaging study of delayed verbal memory in HIV-infected women demonstrated alterations in hippocampal function with decreased activation during verbal encoding and increased during verbal retrieval.96 Importantly, the magnitude of those alterations correlated with worse delayed recall on the HVLT.96 Together, these findings suggest that cocaine and heroin use in HIV-infected women may also lead to further alterations in hippocampal function during verbal encoding.
Our study had several limitations. First, self-report data were used to determine drug use categories. If women who had recently used illicit drugs reported never using cocaine, the impact of illicit drug use on cognition may be underestimated. Second, toxicology screens were not administered in conjunction with neurocognitive testing, so it is possible that the recent users could have been under the influence of drugs or experiencing drug withdrawal. WIHS staff are trained in detecting illicit substance use and reschedule women for cognitive testing if they seem to be under the influence of illicit substances. Third, given the use of multiple illicit substances in our cohort, we could not fully disentangle the effects of different substances on cognition. We found that cocaine use (with or without heroin) predicted worse total learning, learning slope, and delayed recall and heroin use (with or without cocaine) predicted worse total learning and learning slope among HIV-infected women. Fourth, although effect sizes are 0.11 or lower, the effect sizes for the interaction between serostatus and drug use are equal to or exceed the effect sizes associated with HIV serostatus alone or drug use alone. Fifth, only 2 neurocognitive tests were administered, so we could not evaluate effects across a broader spectrum of cognitive domains. Lastly, the cross-sectional design of this study precludes the possibility of examining causality. We presume that illicit drug use leads to poor memory performance, but it is possible that learning and memory deficits preceded drug use for at least some women. The last 2 limitations are being now addressed with the collection of longitudinal cognitive data in the WIHS.
1. Sacktor N, McDermott MP, Marder K, et al.. HIV
-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002;8:136–142.
2. Heaton RK, Grant I, Butters N, et al.. The HNRC 500—neuropsychology of HIV
infection at different disease stages. HIV
Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1:231–251.
3. Benedict RH, Mezhir JJ, Walsh K, et al.. Impact of human immunodeficiency virus type-1-associated cognitive dysfunction on activities of daily living and quality of life. Arch Clin Neuropsychol. 2000;15:535–544.
4. Heaton RK, Velin RA, McCutchan JA, et al.. Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV
Neurobehavioral Research Center. Psychosom Med. 1994;56:8–17.
5. van Gorp WG, Rabkin JG, Ferrando SJ, et al.. Neuropsychiatric predictors of return to work in HIV
/AIDS. J Int Neuropsychol Soc. 2007;13:80–89.
6. Cattie JE, Woods SP, Arce M, et al.. Construct validity of the item-specific deficit approach to the California verbal learning test (2nd Ed) in HIV
infection. Clin Neuropsychol. 2012;26:288–304.
7. Scott JC, Woods SP, Patterson KA, et al.. Recency effects in HIV
-associated dementia are characterized by deficient encoding. Neuropsychologia. 2006;44:1336–1343.
8. Woods SP, Scott JC, Dawson MS, et al.. Construct validity of Hopkins Verbal Learning Test-Revised component process measures in an HIV
-1 sample. Arch Clin Neuropsychol. 2005;20:1061–1071.
9. Beatty WW, Katzung VM, Moreland VJ, et al.. Neuropsychological performance of recently abstinent alcoholics and cocaine
abusers. Drug Alcohol Depend. 1995;37:247–253.
10. Berry J, van Gorp WG, Herzberg DS, et al.. Neuropsychological deficits in abstinent cocaine
abusers: preliminary findings after two weeks of abstinence. Drug Alcohol Depend. 1993;32:231–237.
11. Bolla KI, Funderburk FR, Cadet JL. Differential effects of cocaine
alcohol on neurocognitive performance. Neurology. 2000;54:2285–2292.
12. O'Malley S, Adamse M, Heaton RK, et al.. Neuropsychological impairment in chronic cocaine
abusers. Am J Drug Alcohol Abuse. 1992;18:131–144.
13. Strickland TL, Mena I, Villanueva-Meyer J, et al.. Cerebral perfusion and neuropsychological consequences of chronic cocaine
use. J Neuropsychiatry Clin Neurosci. 1993;5:419–427.
14. Darke S, Sims J, McDonald S, et al.. Cognitive impairment among methadone maintenance patients. Addiction. 2000;95:687–695.
15. Bolla KI, Rothman R, Cadet JL. Dose-related neurobehavioral effects of chronic cocaine
use. J Neuropsychiatry Clin Neurosci. 1999;11:361–369.
16. Hester R, Garavan H. Executive dysfunction in cocaine
addiction: evidence for discordant frontal, cingulate, and cerebellar activity. J Neurosci. 2004;24:11017–11022.
17. Grant S, Contoreggi C, London ED. Drug abusers show impaired performance in a laboratory test of decision making. Neuropsychologia. 2000;38:1180–1187.
18. Mintzer MZ, Stitzer ML. Cognitive impairment in methadone maintenance patients. Drug Alcohol Depend. 2002;67:41–51.
19. Aksenov MY, Aksenova MV, Nath A, et al.. Cocaine
-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology. 2006;27:217–228.
20. Aksenov MY, Hasselrot U, Wu G, et al.. Temporal relationships between HIV
-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum. Brain Res. 2003;987:1–9.
21. Bagasra O, Pomerantz RJ. Human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells in the presence of cocaine
. J Infect Dis. 1993;168:1157–1164.
22. Dhillon NK, Williams R, Peng F, et al.. Cocaine
-mediated enhancement of virus replication in macrophages: implications for human immunodeficiency virus-associated dementia. J Neurovirol. 2007;13:483–495.
23. Fiala M, Eshleman AJ, Cashman J, et al.. Cocaine
increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J Neurovirol. 2005;11:281–291.
24. Fiala M, Gan XH, Zhang L, et al.. Cocaine
enhances monocyte migration across the blood-brain barrier. Cocaine
's connection to AIDS dementia and vasculitis? Adv Exp Med Biol. 1998;437:199–205.
25. Gekker G, Hu S, Wentland MP, et al.. Kappa-opioid receptor ligands inhibit cocaine
-1 expression in microglial cells. J Pharmacol Exp Ther. 2004;309:600–606.
26. Harrod SB, Mactutus CF, Fitting S, et al.. Intra-accumbal Tat1-72 alters acute and sensitized responses to cocaine
. Pharmacol Biochem Behav. 2008;90:723–729.
27. Kendall SL, Anderson CF, Nath A, et al.. Gonadal steroids differentially modulate neurotoxicity of HIV
: testosterone and ICI 182,780 sensitive mechanism. BMC Neurosci. 2005;6:40.
28. Peterson PK, Gekker G, Chao CC, et al.. Cocaine
-1 replication in human peripheral blood mononuclear cell cocultures. Involvement of transforming growth factor-beta. J Immunol. 1991;146:81–84.
29. Reynolds JL, Mahajan SD, Bindukumar B, et al.. Proteomic analysis of the effects of cocaine
on the enhancement of HIV
-1 replication in normal human astrocytes (NHA). Brain Res. 2006;1123:226–236.
30. Roth MD, Tashkin DP, Choi R, et al.. Cocaine
enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. J Infect Dis. 2002;185:701–705.
31. Turchan J, Anderson C, Hauser KF, et al.. Estrogen protects against the synergistic toxicity by HIV
proteins, methamphetamine and cocaine
. BMC Neurosci. 2001;2:3.
32. Brack-Werner R. Astrocytes: HIV
cellular reservoirs and important participants in neuropathogenesis. AIDS. 1999;13:1–22.
33. Gurwell JA, Nath A, Sun Q, et al.. Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro. Neuroscience. 2001;102:555–563.
34. Khurdayan VK, Buch S, El-Hage N, et al.. Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV
-1 Tat exposure in vitro. Eur J Neurosci. 2004;19:3171–3182.
35. Hu S, Sheng WS, Lokensgard JR, et al.. Morphine potentiates HIV
-1 gp120-induced neuronal apoptosis. J Infect Dis. 2005;191:886–889.
36. Venkatesan A, Nath A, Ming GL, et al.. Adult hippocampal neurogenesis: regulation by HIV
and drugs of abuse. Cell Mol Life Sci. 2007;64:2120–2132.
37. Maki PM, Martin-Thormeyer E. HIV
. Neuropsychol Rev. 2009;19:204–214.
38. Lejuez CW, Bornovalova MA, Reynolds EK, et al.. Risk factors in the relationship between gender and crack/cocaine
. Exp Clin Psychopharmacol. 2007;15:165–175.
39. O'Brien MS, Anthony JC. Risk of becoming cocaine
dependent: epidemiological estimates for the United States, 2000-2001. Neuropsychopharmacology. 2005;30:1006–1018.
40. Chen K, Kandel D. Relationship between extent of cocaine
use and dependence among adolescents and adults in the United States. Drug Alcohol Depend. 2002;68:65–85.
41. Edlin BR, Irwin KL, Faruque S, et al.. Intersecting epidemics—crack cocaine
use and HIV
infection among inner-city young adults. Multicenter Crack Cocaine
Infection Study Team. N Engl J Med. 1994;331:1422–1427.
42. Baum MK, Rafie C, Lai S, et al.. Crack-cocaine
use accelerates HIV
disease progression in a cohort of HIV
-positive drug users. J Acquir Immune Defic Syndr. 2009;50:93–99.
43. Webber MP, Schoenbaum EE, Gourevitch MN, et al.. A prospective study of HIV
disease progression in female and male drug users. AIDS. 1999;13:257–262.
44. Cook JA, Burke-Miller JK, Cohen MH, et al.. Crack cocaine
, disease progression, and mortality in a multicenter cohort of HIV
-1 positive women
. AIDS. 2008;22:1355–1363.
45. Thorpe LE, Frederick M, Pitt J, et al.. Effect of hard-drug use on CD4 cell percentage, HIV
RNA level, and progression to AIDS-defining class C events among HIV
. J Acquir Immune Defic Syndr. 2004;37:1423–1430.
46. Carey CL, Woods SP, Rippeth JD, et al.. Initial validation of a screening battery for the detection of HIV
-associated cognitive impairment. Clin Neuropsychol. 2004;18:234–248.
47. Hinkin CH, Castellon SA, Hardy DJ, et al.. Computerized and traditional stroop task dysfunction in HIV
-1 infection. Neuropsychology. 1999;13:306–316.
48. Martin EM, Novak RM, Fendrich M, et al.. Stroop performance in drug users classified by HIV
and hepatitis C virus serostatus. J Int Neuropsychol Soc. 2004;10:298–300.
49. Moore DJ, Masliah E, Rippeth JD, et al.. Cortical and subcortical neurodegeneration is associated with HIV
neurocognitive impairment. AIDS. 2006;20:879–887.
50. Woods SP, Rippeth JD, Frol AB, et al.. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV
. J Clin Exp Neuropsychol. 2004;26:759–778.
51. Bacon MC, von Wyl V, Alden C, et al.. The Women
's Interagency HIV
Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol. 2005;12:1013–1019.
52. Barkan SE, Melnick SL, Preston-Martin S, et al.. The Women
's Interagency HIV
Study. WIHS Collaborative Study Group. Epidemiology. 1998;9:117–125.
53. Maki P, Rubin LH, Cohen M, et al.. Depressive symptoms are increased in the early perimenopausal stage in ethnically diverse HIV
+ and HIV
. Menopause. 2012;19:1215–1223.
54. Benedict RHB, Schretlen D, Groninger L, et al.. Hopkins Verbal Learning Test—Revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998;12:43–55.
55. Comalli Jr PE, Wapner S, Werner H. Interference effects of Stroop color-word test in childhood, adulthood, and aging. J Genet Psychol. 1962;100:47–53.
56. Jastak S, Wilkinson GS, Jastak J. Wide Range Achievement Test-Revised. Indianapolis, IN: Jastak Associates Inc; 1984.
57. Manly JJ, Jacobs DM, Touradji P, et al.. Reading level attenuates differences in neuropsychological test performance between African American and White elders. J Int Neuropsychol Soc. 2002;8:341–348.
58. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.
59. Cherner M, Letendre S, Heaton RK, et al.. Hepatitis C augments cognitive deficits associated with HIV
infection and methamphetamine. Neurology. 2005;64:1343–1347.
60. Durvasula RS, Miller EN, Myers HF, et al.. Predictors of neuropsychological performance in HIV
. J Clin Exp Neuropsychol. 2001;23:149–163.
61. Goggin KJ, Zisook S, Heaton RK, et al.. Neuropsychological performance of HIV
-1 infected men with major depression. HNRC Group. HIV
Neurobehavioral Research Center. J Int Neuropsychol Soc. 1997;3:457–464.
62. Letendre SL, Cherner M, Ellis RJ, et al.. The effects of hepatitis C, HIV
, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS. 2005;19(suppl 3):S72–S78.
63. Manly JJ, Smith C, Crystal HA, et al.. Relationship of ethnicity, age, education, and reading level to speed and executive function among HIV
+ and HIV
: The Women
's Interagency HIV
Study (WIHS) Neurocognitive Substudy. J Clin Exp Neuropsychol. 2011;33:853–863.
64. Richardson JL, Nowicki M, Danley K, et al.. Neuropsychological functioning in a cohort of HIV
- and hepatitis C virus-infected women
. AIDS. 2005;19:1659–1667.
65. Ryan EL, Morgello S, Isaacs K, et al.. Neuropsychiatric impact of hepatitis C on advanced HIV
. Neurology. 2004;62:957–962.
66. Valcour V, Maki P, Bacchetti P, et al.. Insulin resistance and cognition
-infected and HIV
-uninfected adult women
: The Women
's Interagency HIV
Study. AIDS Res Hum Retroviruses. 2012;28:447–453.
67. Willenbring ML, Massey SH, Gardner MB. Helping patients who drink too much: an evidence-based guide for primary care clinicians. Am Fam Physician. 2009;80:44–50.
68. Hinkin CH, Castellon SA, Durvasula RS, et al.. Medication adherence among HIV
+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59:1944–1950.
69. Martin-Thormeyer EM, Paul RH. Drug abuse and hepatitis C infection as comorbid features of HIV
associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev. 2009;19:215–231.
70. Rippeth JD, Heaton RK, Carey CL, et al.. Methamphetamine dependence increases risk of neuropsychological impairment in HIV
infected persons. J Int Neuropsychol Soc. 2004;10:1–14.
71. Chang L, Ernst T, Speck O, et al.. Additive effects of HIV
and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry. 2005;162:361–369.
72. Ances BM, Vaida F, Cherner M, et al.. HIV
and chronic methamphetamine dependence affect cerebral blood flow. J Neuroimmune Pharmacol. 2011;6:409–419.
73. Durvasula RS, Myers HF, Satz P, et al.. HIV
, and neuropsychological performance in African American men. J Int Neuropsychol Soc. 2000;6:322–335.
74. Gonzalez R, Jacobus J, Amatya AK, et al.. Deficits in complex motor functions, despite no evidence of procedural learning deficits, among HIV
+ individuals with history of substance dependence. Neuropsychology. 2008;22:776–786.
75. Martin EM, Nixon H, Pitrak DL, et al.. Characteristics of prospective memory deficits in HIV
-seropositive substance-dependent individuals: preliminary observations. J Clin Exp Neuropsychol. 2007;29:496–504.
76. Martin EM, Pitrak DL, Rains N, et al.. Delayed nonmatch-to-sample performance in HIV
-seropositive and HIV
-seronegative polydrug abusers. Neuropsychology. 2003;17:283–288.
77. Martin EM, Sullivan TS, Reed RA, et al.. Auditory working memory in HIV
-1 infection. J Int Neuropsychol Soc. 2001;7:20–26.
78. Martin EM, Pitrak DL, Weddington W, et al.. Cognitive impulsivity and HIV
serostatus in substance dependent males. J Int Neuropsychol Soc. 2004;10:931–938.
79. Mason KI, Campbell A, Hawkins P, et al.. Neuropsychological functioning in HIV
-positive African-American women
with a history of drug use. J Natl Med Assoc. 1998;90:665–674.
80. Hanlon CA, Dufault DL, Wesley MJ, et al.. Elevated gray and white matter densities in cocaine
abstainers compared to current users. Psychopharmacology (Berl). 2011;218:681–692.
81. Di Sclafani V, Tolou-Shams M, Price LJ, et al.. Neuropsychological performance of individuals dependent on crack-cocaine
, or crack-cocaine
and alcohol, at 6 weeks and 6 months of abstinence. Drug Alcohol Depend. 2002;66:161–171.
82. Gould RW, Gage HD, Nader MA. Effects of chronic cocaine
self-administration on cognition
and cerebral glucose utilization in Rhesus monkeys. Biol Psychiatry. 2012;72:856–863.
83. Meade CS, Conn NA, Skalski LM, et al.. Neurocognitive impairment and medication adherence in HIV
patients with and without cocaine
dependence. J Behav Med. 2011;34:128–138.
84. Byrd DA, Fellows RP, Morgello S, et al.. Neurocognitive impact of substance use in HIV
infection. J Acquir Immune Defic Syndr. 2011;58:154–162.
85. Levine AJ, Hardy DJ, Miller E, et al.. The effect of recent stimulant use on sustained attention in HIV
-infected adults. J Clin Exp Neuropsychol. 2006;28:29–42.
86. Woicik PA, Moeller SJ, Alia-Klein N, et al.. The neuropsychology of cocaine
addiction: recent cocaine
use masks impairment. Neuropsychopharmacology. 2009;34:1112–1122.
87. Verdejo-Garcia AJ, Lopez-Torrecillas F, Aguilar de Arcos F, et al.. Differential effects of MDMA, cocaine
, and cannabis use severity on distinctive components of the executive functions in polysubstance users: a multiple regression analysis. Addict Behav. 2005;30:89–101.
88. Bolla K, Ernst M, Kiehl K, et al.. Prefrontal cortical dysfunction in abstinent cocaine
abusers. J Neuropsychiatry Clin Neurosci. 2004;16:456–464.
89. Franklin TR, Acton PD, Maldjian JA, et al.. Decreased gray matter concentration in the insular, orbitofrontal, cingulate, and temporal cortices of cocaine
patients. Biol Psychiatry. 2002;51:134–142.
90. Volkow ND, Fowler JS, Wang GJ, et al.. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine
abusers. Synapse. 1993;14:169–177.
91. Volkow ND, Hitzemann R, Wang GJ, et al.. Long-term frontal brain metabolic changes in cocaine
abusers. Synapse. 1992;11:184–190.
92. Volkow ND, Mullani N, Gould KL, et al.. Cerebral blood flow in chronic cocaine
users: a study with positron emission tomography. Br J Psychiatry. 1988;152:641–648.
93. Delis DC, Peavy G, Heaton R, et al.. Do patients with HIV
-associated minor cognitive/motor disorder exhibit a “subcortical” memory profile? Evidence using the California Verbal Learning Test. Assessment. 1995;2:151–165.
94. Gongvatana A, Woods SP, Taylor MJ, et al.. Semantic clustering inefficiency in HIV
-associated dementia. J Neuropsychiatry Clin Neurosci. 2007;19:36–42.
95. Peavy G, Jacobs D, Salmon DP, et al.. Verbal memory performance of patients with human immunodeficiency virus infection: evidence of subcortical dysfunction. The HNRC Group. J Clin Exp Neuropsychol. 1994;16:508–523.
96. Maki PM, Cohen MH, Weber K, et al.. Impairments in memory and hippocampal function in HIV
-positive vs HIV
: a preliminary study. Neurology. 2009;72:1661–1668.